Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia.

We report the discovery of a series of imidazo[1,2-a]pyrazine derivatives as novel inhibitors of phosphodiesterase 10A (PDE10A). In a high-throughput screening campaign we identified the imidazopyrazine derivative 1, a PDE10A inhibitor with limited selectivity versus the other phosphodiesterases (PDEs). Subsequent investigation of 1 and replacement of the trimethoxyphenyl group by a (methoxyethyl)pyrazole moiety maintained PDE10A inhibition but enhanced selectivity against the other PDEs. Systematic examination and analysis of structure-activity and structure-property relationships resulted in the discovery of 2, an in vitro potent and selective inhibitor of PDE10A with high striatal occupancy of PDE10A, promising in vivo efficacy in different rodent behavioral models of schizophrenia, and a good pharmacokinetic profile in rats.

Citation

José Manuel Bartolomé-Nebreda, Francisca Delgado, María Luz Martín-Martín, Carlos M Martínez-Viturro, Joaquín Pastor, Han Min Tong, Laura Iturrino, Gregor J Macdonald, Wendy Sanderson, Anton Megens, Xavier Langlois, Marijke Somers, Greet Vanhoof, Susana Conde-Ceide. Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia. Journal of medicinal chemistry. 2014 May 22;57(10):4196-212

Mesh Tags

Substances

PMID: 24758746

search → result